Last updated: February 19, 2026
Amlodipine besylate, a calcium channel blocker used primarily for hypertension and angina, has a global supply chain involving manufacturers, bulk drug producers, and authorized distributors. The drug’s suppliers are predominantly located in India, China, and the United States, with some Chinese and Indian companies dominating production capacity.
Major Active Pharmaceutical Ingredient (API) Producers
India
- Sun Pharma Advanced Research Company Ltd.
API manufacturing facility located in Gujarat. It produces amlodipine besylate for the domestic and export markets.
- Torrent Pharmaceuticals Ltd.
Maintains API manufacturing facilities supporting global supply chains, including amlodipine besylate.
- Aurobindo Pharma Ltd.
A prominent API supplier, with production capabilities in Hyderabad and other sites.
- Hetero Drugs Ltd.
Offers APIs including amlodipine besylate, with export to global markets.
China
- Zhejiang Hisun Pharmaceutical Co., Ltd.
Produces bulk APIs, including amlodipine besylate, primarily for Chinese and export markets.
- Qingdao Zhonghe Pharmaceutical Co., Ltd.
Supplies APIs, including amlodipine besylate, to international markets.
- Jiangsu Hengrui Medicine Co., Ltd.
Supplies a range of cardiovascular APIs, including amlodipine.
United States
- LGM Pharma
Distributes APIs globally, sourcing from Indian and Chinese manufacturers.
- Amneal Pharmaceuticals
Focuses on finished dosage forms; APIs are sourced from major Indian and Chinese manufacturers.
Major Finished Dosage Form Suppliers
- Mylan (now part of Viatris)
Supplies generic tablets globally, sourced from Indian and Chinese API producers.
- AstraZeneca
Markets branded and generic versions, relying on global API supply chains.
Supply Chain Characteristics
| Attribute |
Details |
| Production Concentration |
60-70% of API production occurs in India and China globally. |
| Regulatory Requirements |
Suppliers compliant with US FDA, EMA, and WHO GMP standards. |
| Market Distribution |
API suppliers serve both generic manufacturers and branded pharmaceutical companies. |
Key Considerations for Procurement
- Regulatory Compliance: Suppliers must meet regulatory standards like US FDA, EMA, or WHO GMP.
- Supply Security: India dominates API production, creating potential geographic supply risks.
- Quality Assurance: Uniform quality standards are critical for APIs used in smaller margins markets.
- Pricing Dynamics: Indian suppliers typically offer lower prices than Chinese or Western producers.
- Capacity Limitations: Production capacity gaps may influence supply stability, especially during pandemics or geopolitical tensions.
Conclusion
The primary API manufacturers for amlodipine besylate are concentrated in India and China, with Indian firms leading in production capacity and cost competitiveness. Suppliers for finished dosage forms include global firms like Mylan and AstraZeneca, which source APIs from these regions. Regulatory compliance and supply chain resilience influence procurement decisions.
Key Takeaways
- India accounts for approximately 60-70% of global amlodipine besylate API production.
- China produces APIs, but Indian manufacturers dominate in volume and cost.
- Most suppliers comply with international regulatory standards.
- Supply chain risks depend on geopolitical and pandemic-related factors.
- Procurement strategies should include diversified sourcing and quality assurance measures.
FAQs
1. Which countries dominate amlodipine besylate API production?
India and China produce the majority of APIs, with India holding roughly 60-70% of total capacity.
2. Who are the leading API suppliers for amlodipine besylate?
Sun Pharma, Aurobindo Pharma, Torrent Pharmaceuticals in India, and Zhejiang Hisun in China.
3. What standards do API suppliers comply with?
Suppliers typically meet US FDA, EMA, and WHO GMP standards.
4. Are there concerns about API supply stability?
Yes, reliance on India and China poses risks, especially amid geopolitical tensions or supply chain disruptions.
5. How do finished dosage form producers ensure quality?
Through stringent supplier qualification, batch testing, and compliance with international regulatory standards.
References
- World Health Organization. (2022). WHO Global Drug Facility. API Market Overview.
- U.S. Food and Drug Administration. (2022). Data on API manufacturing facilities.
- IQVIA. (2023). Global API market analysis.
- Indian Drug Manufacturers Association. (2022). API production statistics.
- China Pharmaceutical Industry Association. (2022). API manufacturing capacity report.
